Ausam Biotech to Ink Licensing Deal for Proteomic-Based Diagnostic | GenomeWeb

Ausam Biotech to Ink Licensing Deal for Proteomic-Based Diagnostic

Oct 03, 2001

WASHINGTON, DC, Oct. 3 – Ausam Biotechnologies is set to strike a licensing deal in the current quarter with a pair of "major US pharmaceutical companies" for its proteomic-based kidney disease diagnostic, the company’s CEO told GenomeWeb on Wednesday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Halt Under Consideration

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

How's It Going to Go Over?

The Associated Press reports that gene-edited food may soon be for sale.

Meetings on Fetal Research

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

This Week in Cell

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.